CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.66%, Turnover Reaches HKD 6.9758 Million
Newtimespace News: As of 10:41 on July 14, CSOP Hang Seng Biotech ETF (03174.HK) stood at HKD 3.362, up 0.66%. The ETF opened at HKD 3.338, with the latest net asset value (NAV) at HKD 3.330, a premium of 0.30%, a turnover of approximately HKD 6.9758 million, and assets under management of approximately HKD 845 million.
CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The index covers biotech companies listed in Hong Kong, focusing on pharmaceuticals, biotechnology, medical equipment, and other fields, capturing innovative growth opportunities in the Hong Kong biotech sector.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP Biotech(03174.HK) up 3.22%, Hengrui Novo license up to $2.6bn
- HK shares ETFs Daily Report: ChinaAMC Innovative Drugs Leads Gains; Biotech and Semiconductors Strengthen, Hang Seng TECH Retreats — September 29, 2026
- CSOP Biotech(03174.HK) up 2.89%, AstraZeneca $2bn Akeso partner deal
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 4.84% Intraday after Ten Departments Issue the Pharmaceutical Industry 15th Five-Year Plan, Targeting 20%+ Annual Growth for Innovative Drugs
- CSOP Hang Seng Biotech ETF (03174.HK) up 4.79% intraday on policy catalysts